biotech / news / / MarketScreener
AstraZeneca shares fell 1.7% to 13,714.00 pence on Friday morning in London.
AstraZeneca's Truqap combo won US advisory committee backing for PTEN-deficient metastatic prostate cancer.
KEY POINTS
- Phase-three data showed Truqap reduced progression or death risk by 19% in this prostate cancer group.
- AstraZeneca's camizestrant failed to secure US advisory approval for first-line advanced breast cancer use.
- Camizestrant showed strong disease progression reduction, but data on overall survival remains immature.
- Both Truqap and camizestrant regulatory reviews are ongoing in the EU as well.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →